Skip to content

A Study Assessing Heart Rate Variability During Anesthesia Induction with Remimazolam Besylate and Remifentanil Coadministration in Elderly Patients.

A Study Assessing Heart Rate Variability During Anesthesia Induction with Remimazolam Besylate and Remifentanil Coadministration in Elderly Patients.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105514
Enrollment
Unknown
Registered
2025-07-04
Start date
2025-10-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Rate Variability (HRV)

Interventions

Group R1 (Trial 1):Remimazolam 0.15 mg
Group R2 (Trial 1):Remimazolam 0.25 mg
Remimazolam tosylate group (trial 2):The effective induction dose of remimazolam tosilate combined with remifentanil determined in Experiment I
Propofol group (trial 2):The effective induction dose of propofol combined with remifentanil.

Sponsors

The Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective surgery, age 60~80 years old, body mass index (BMI) 19.0-26.0 kg/m^2, ASA I-III. grade; 2. No history of long-term smoking and alcoholism, no abnormalities in heart, lung, liver and kidney function, no spinal cord injury, endocrine diseases, no hyperthyroidism or hypothyroidism, no acid-base imbalance and electrolyte disorders; 3. Have not used drugs and glucocorticoids that affect autonomic nerve function within two weeks before surgery; 4. Normal cognitive and mental state.

Exclusion criteria

Exclusion criteria: 1. Conventional electrocardiogram (ECG) shows interference with ECG analysis, such as left and right bundle branch block, left ventricular hypertrophy, atrial fibrillation or flutter, second- or third-degree atrioventricular block, QT interval prolongation; 2. Patients with diseases of the central nervous system and autonomic nervous system; Those who use ß receptor blockers or drugs affecting the central nervous system before surgery; 3. Those who are allergic to benzodiazepines and any of the ingredients of this product or have a history of severe allergies in the past, combined with head injury, intracranial hypertension or a history of cerebrovascular disease.

Design outcomes

Primary

MeasureTime frame
Heart Rate Variability (HRV);

Secondary

MeasureTime frame
Heart rate;Blood pressure;Blood oxygen saturation;

Countries

China

Contacts

Public ContactZhong Yi

The Affiliated Hospital of Guizhou Medical University

490173559@qq.com+86 133 1221 5880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026